Novartis Hits Teva With Another Lotrel Suit

Law360, New York (February 14, 2008, 12:00 AM EST) -- Novartis International AG now has two patent suits pending against generics maker Teva Pharmaceuticals USA Inc. over the blockbuster hypertension drug Lotrel, lodging a new complaint after Teva submitted a bid to make its proposed generic in different dosage strengths.

The Swiss drugmaker filed the latest Lotrel suit against Israeli generics maker Teva Pharmaceutical Industries Ltd's U.S. subsidiary on Feb. 7 in the U.S. District Court for the District of New Jersey.

The complaint notes that Novartis filed a suit against Teva USA in September 2004...
To view the full article, register now.